Mansi Shah

3.2k total citations
40 papers, 288 citations indexed

About

Mansi Shah is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Mansi Shah has authored 40 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Mansi Shah's work include Multiple Myeloma Research and Treatments (12 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Mansi Shah is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Mansi Shah collaborates with scholars based in United States, India and Germany. Mansi Shah's co-authors include Zhaoping He, Sam Soundar, Devendra I. Mehta, Scott Penfil, John McCloskey, Richard J. Schmidt, Robert O’Reilly, Victoria Chernyak, Attaya Suvannasankha and James E. Hoffman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Mansi Shah

30 papers receiving 278 citations

Peers

Countries citing papers authored by Mansi Shah

Since Specialization

Citations

This map shows the geographic impact of Mansi Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mansi Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mansi Shah more than expected).

Fields of papers citing papers by Mansi Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mansi Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mansi Shah. The network helps show where Mansi Shah may publish in the future.

Co-authorship network of co-authors of Mansi Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Mansi Shah. A scholar is included among the top collaborators of Mansi Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mansi Shah. Mansi Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort 2025 ·British Journal of Haematology ·(unknown), Samer Al Hadidi, Meera Mohan, Mansi Shah	0
2	Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals 2025 ·Cancers ·(unknown), Shebli Atrash, (unknown), Abdullah Khan, (unknown), Hira Shaikh, Christopher Strouse, (unknown), (unknown), Nausheen Ahmed, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, (unknown), Joseph P. McGuirk, (unknown), Mansi Shah, Al‐Ola Abdallah	0
3	Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study 2025 ·Blood Cancer Journal ·Samer Al Hadidi, Anikó Szabó, (unknown), (unknown), (unknown), (unknown), (unknown), Binod Dhakal, Divaya Bhutani, Sharmilan Thanendrarajan, Maurizio Zangari, Anita D’Souza, Suzanne Lentzsch, Frits van Rhee, Rajshekhar Chakraborty, Carolina Schinke, Meera Mohan, Mansi Shah	0
4	The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia 2025 ·Blood Advances ·(unknown), Sharmilan Thanendrarajan, (unknown), Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, (unknown), Anita D’Souza, Nishi Shah, Mansi Shah, Meera Mohan, Carolina Schinke	0
5	Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial 2025 ·Clinical Lymphoma Myeloma & Leukemia ·James E. Hoffman, Naresh Bumma, Joshua Richter, Madhav V. Dhodapkar, Hans C. Lee, Attaya Suvannasankha, Jeffrey A. Zonder, Joseph Maly, Mansi Shah, Rachid Baz, (unknown), (unknown), Michelle DeVeaux, Karen Rodriguez Lorenc, (unknown), Karina Knorr, James Harnett, Qiufei Ma, Sundar Jagannath	1
6	Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients 2024 ·Blood ·(unknown), Mansi Shah, Nishi Shah, (unknown), Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D’Souza, Anikó Szabó, Meera Mohan	0
7	Racial disparities in the diagnosis of disruptive behavior disorders: a U.S. national inpatient sample analysis 2024 ·Frontiers in Psychiatry ·(unknown), (unknown), Mansi Shah, Claudia Lugo‐Candelas	0
8	Peripheral Ulcerative Keratitis as a Manifestation of Drug-Induced Cicatrizing Conjunctivitis 2023 ·Cureus ·(unknown), Khushi Shah, Mansi Shah, (unknown)	1
9	Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer 2023 ·Breast Cancer Research and Treatment ·(unknown), Melissa Accordino, (unknown), Mansi Shah, Jason D. Wright, Dawn L. Hershman	6
10	DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD 2023 ·Inflammatory Bowel Diseases ·Mansi Shah, Zonghui Ma, Haiying Chen, Yingzi Cong, (unknown), Erik Rytting, Bing Tian	1
11	LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. 2023 ·Journal of Clinical Oncology ·Hans C. Lee, Naresh Bumma, Joshua Richter, Madhav V. Dhodapkar, James E. Hoffman, Attaya Suvannasankha, Jeffrey A. Zonder, Mansi Shah, Suzanne Lentzsch, Joseph Maly, Jing Christine Ye, Ka Lung Wu, (unknown), (unknown), Anita Boyapati, Anasuya Hazra, Karen Rodriguez-Lorenc, Glenn S. Kroog, Yariv Houvras, Sundar Jagannath	37
12	DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD 2023 ·Gastroenterology ·Mansi Shah, Zonghui Ma, Haiying Chen, Yingzi Cong, (unknown), Erik Rytting, Bing Tian	1
13	Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma 2021 ·Current Hematologic Malignancy Reports ·(unknown), Mansi Shah, Rajat Bannerji	4
14	COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Mansi Shah, (unknown), (unknown), (unknown), Yong Lin, Dennis Cooper	8
15	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer 2021 ·Cancer Discovery ·Arielle Elkrief, Julie Wu, Chinmay Jani, Kyle T. Enriquez, Michael Glover, Mansi Shah, Hira Shaikh, Alicia Beeghly‐Fadiel, Benjamin French, Sachin R. Jhawar, Douglas B. Johnson, Rana R. McKay, Donna R. Rivera, Daniel Y. Reuben, (unknown), (unknown), Donald C. Vinh, Sanjay Mishra, Jeremy L. Warner	23
16	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies 2021 ·Cancer Chemotherapy and Pharmacology ·Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice P. Chen, Jan H. Beumer, Janice M. Mehnert	2
17	Combination drug regimens for metastatic clear cell renal cell carcinoma 2020 ·World Journal of Clinical Oncology ·(unknown), (unknown), Mansi Shah, Tina Mayer, Eric A. Singer	16
18	Transient arterial phase respiratory motion-related artifact in MR imaging of the liver: an analysis of four different gadolinium-based contrast agents 2016 ·Clinical Imaging ·Mansi Shah, Milana Flusberg, Viktoriya Paroder, Alla M. Rozenblit, Victoria Chernyak	18
19	Direct Liver Invasion from a Gastric Adenocarcinoma as an Initial Presentation of Extranodal Tumor Spread 2012 ·Case Reports in Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Mansi Shah, (unknown), Paul Mustacchia	1
20	Assessment of the prevalence of microaspiration by gastric pepsin in the airway of ventilated children 2007 ·Acta Paediatrica ·(unknown), Zhaoping He, Sam Soundar, (unknown), Mansi Shah, Scott Penfil, John McCloskey, Devendra I. Mehta	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact